173 related articles for article (PubMed ID: 22105113)
1. Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.
Sotosek S; Sotosek Tokmadzic V; Mrakovcic-Sutic I; Tomas MI; Dominovic M; Tulic V; Sutic I; Maricic A; Sokolic J; Sustic A
Wien Klin Wochenschr; 2011 Dec; 123(23-24):718-25. PubMed ID: 22105113
[TBL] [Abstract][Full Text] [Related]
2. Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer.
Tokmadžić VS; Tomaš MI; Sotošek S; Laškarin G; Dominović M; Tulić V; Dorđević G; Sustić A; Mrakovčić-Šutić I
Scand J Immunol; 2011 Oct; 74(4):368-76. PubMed ID: 21535078
[TBL] [Abstract][Full Text] [Related]
3. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
[TBL] [Abstract][Full Text] [Related]
4. Analysis of NK cell activity, lymphocyte reactivity to mitogens and serotest PSA and TPS values in patients with primary and disseminated prostate cancer, PIN and BPH.
Kastelan M; Kovacić K; Tarle R; Kraljić I; Tarle M
Anticancer Res; 1997; 17(3B):1671-5. PubMed ID: 9179216
[TBL] [Abstract][Full Text] [Related]
5. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.
Ebelt K; Babaryka G; Figel AM; Pohla H; Buchner A; Stief CG; Eisenmenger W; Kirchner T; Schendel DJ; Noessner E
Prostate; 2008 Jan; 68(1):1-10. PubMed ID: 17948280
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate.
Elsässer-Beile U; Przytulski B; Gierschner D; Grussenmeyer T; Katzenwadel A; Leiber C; Deckart A; Wetterauer U
Prostate; 2000 Sep; 45(1):1-7. PubMed ID: 10960837
[TBL] [Abstract][Full Text] [Related]
7. [Percentages and functions of natural killer cell subsets in peripheral blood of patients with severe aplastic anemia].
Li ZS; Shao ZH; Fu R; Wang J; Li LJ; Zhang T; Wang HQ; Wu YH; Ruan EB; Song J; Qu W; Liu H; Xing LM; Wang XM; Liang Y; Guan J; Wang GJ
Zhonghua Yi Xue Za Zhi; 2011 Apr; 91(16):1084-7. PubMed ID: 21609587
[TBL] [Abstract][Full Text] [Related]
8. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
[TBL] [Abstract][Full Text] [Related]
9. An immunohistochemical study of T and B lymphocyte density in prostatic hyperplasia and prostate carcinoma in dogs.
Palmieri C; Hood G; Fonseca-Alves CE; Laufer-Amorim R; Allavena R
Res Vet Sci; 2019 Feb; 122():189-192. PubMed ID: 30529932
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
[TBL] [Abstract][Full Text] [Related]
11. Clinical Implications of Peripheral CD3+CD69+ T-Cell And CD8+CD28+ T-Cell Proportions in Patients Prior to Radical Prostatectomy.
Zhang Y; Zhang Z; Zhang L; Zhao S; Zhao J; Ye Q; Gao Y; Jiang C; Cui D; Xia S; Han B; Jing Y
Urol J; 2020 May; 17(3):257-261. PubMed ID: 31630384
[TBL] [Abstract][Full Text] [Related]
12. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
13. Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis).
Lokant MT; Naz RK
Andrologia; 2015 Apr; 47(3):328-32. PubMed ID: 24620795
[TBL] [Abstract][Full Text] [Related]
14. Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8+ T lymphocytes, NK-cells, and high frequency of CD73+ stromal cells.
Mougola Bissiengou P; Montcho Comlan JG; Atsame Ebang G; Sylla Niang M; Djoba Siawaya JF
Cancer Rep (Hoboken); 2023 Sep; 6 Suppl 1(Suppl 1):e1817. PubMed ID: 37092584
[TBL] [Abstract][Full Text] [Related]
15. T- and NK-cell populations with regulatory phenotype and markers of apoptosis in circulating lymphocytes of patients with CIN3 or microcarcinoma of the cervix: evidence for potential mechanisms of immune suppression.
Kurmyshkina OV; Kovchur PI; Schegoleva LV; Volkova TO
Infect Agent Cancer; 2017; 12():56. PubMed ID: 29075318
[TBL] [Abstract][Full Text] [Related]
16. Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and natural killer cells in peripheral blood.
Lee SK; Kim JY; Jang BW; Hur SE; Na BJ; Lee M; Fukui A; Gilman-Sachs A; Kwak-Kim J
Hum Immunol; 2011 Aug; 72(8):621-6. PubMed ID: 21600259
[TBL] [Abstract][Full Text] [Related]
17. Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia.
Roya N; Fatemeh T; Faramarz MA; Milad SG; Mohammad-Javad S; Najmeh SV; Yousef M; Nader B
Afr Health Sci; 2020 Sep; 20(3):1264-1272. PubMed ID: 33402974
[TBL] [Abstract][Full Text] [Related]
18. Early changes in frequency of peripheral blood lymphocyte subpopulations in severe traumatic brain-injured patients.
Mrakovcic-Sutic I; Tokmadzic VS; Laskarin G; Mahmutefendic H; Lucin P; Zupan Z; Sustic A
Scand J Immunol; 2010 Jul; 72(1):57-65. PubMed ID: 20591077
[TBL] [Abstract][Full Text] [Related]
19. Use of Tregs as a cell-based therapy via CD39 for benign prostate hyperplasia with inflammation.
Jin X; Lin T; Yang G; Cai H; Tang B; Liao X; Li H; Chen X; Gong L; Xu H; Sun Y; Tan P; Yin J; Ma H; Ai J; Wang K; Wei Q; Yang L; Li H
J Cell Mol Med; 2020 May; 24(9):5082-5096. PubMed ID: 32191396
[TBL] [Abstract][Full Text] [Related]
20. Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.
Li WX; Pan HF; Hu JL; Wang CZ; Zhang N; Li J; Li XP; Xu JH; Ye DQ
Clin Rheumatol; 2010 Mar; 29(3):315-23. PubMed ID: 20012119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
